Page 15 - 期货和衍生品行业监管动态(2025年3月刊)
P. 15
期货和衍生品行业监管动态
tariffs as the top factor in their outlook for trading activity, followed by the adoption
of a more business-friendly approach to regulation.
“It’s clear that economics is taking a back seat to politics in terms of what will
drive the derivatives markets in the next few years,” said Walt Lukken, FIA’s
president and chief executive officer. “The political outcomes from last year’s
elections, combined with the ongoing conflict in Ukraine, are creating a lot of
uncertainty in the markets. We will likely see an increase in the trading of derivatives
as market participants balance their risks and adjust their expectations.”
The survey also asked respondents for their views on which asset class had the
greatest potential for growth in 2025 and 2026. Commodities ranked the highest,
followed closely by interest rates and credit. In terms of regions, survey respondents
ranked India and the Middle East as having the highest growth potential outside the
core markets of Europe and North America.
Market structure and technology
The central clearing mandate for the US Treasury securities market led the
market structure issues going into 2025. Although not directly related to derivatives
trading or clearing, many firms involved in derivatives markets will be subject to this
mandate. And many of the firms that provide clearing services for derivatives are
weighing the business opportunities created by the mandate.
The survey asked respondents to draw on their knowledge of clearing to answer
two questions related to the Treasury clearing mandate. First, the survey asked for
feedback on the pros and cons of having more than one clearinghouse for cash
Treasuries and repos. More than half of the survey respondents have a positive view
on competition among clearinghouses, and less than 10% take the opposing view.
Second, the survey asked which attributes are the most important in determining
which clearinghouse to use. The three top choices were cross-margining, margin
methodology and balance sheet treatment.
4